New research indicates that psychedelic drugs could be an alternative for treating mental disorders, according to the Canadian Medical Association journal.
For quite a while, psychedelic drugs such as psilocybin, which is the compound from the so-called “magic mushrooms”, methylenedioxymethamphetamine (MDMA), and lysergic acid diethylamide (LSD) have been classified as dangerous, not to mention if it comes to abusing the use of these drugs. Their medical purpose has been considered infinitesimal, meaning they would have little or actually no use for mental disorders.
But several researchers tend to disagree, therefore they came up with new theories.
Moreover, health experts from Canada, The US, Brazil, Mexico, Peru and Switzerland have been considering that psychedelic drugs could mean an addition to treating mental illnesses including post-traumatic stress disorder (PTSD), addiction, and even anxiety or depression, states which derive from terminal illnesses.
Moreover, it was the Swiss study which specifically took a closer look at LSD’s effects on terminally ill patients, who have been fighting anxiety patterns. It seems these patients, administered with LSD, have shown improvements in their anxiety crisis, whereas no side effects have been recorded.
Larger clinical trials are on their way, as studies could eventually
“conform to the rigorous scientific, ethical and safety standards expected of contemporary medical research,”
said the authors, including Matthew W. Johnson, a professor of psychiatry and behavioral sciences at Johns Hopkins University, also the senior author. Their new analysis has been dubbed “Psychedelic medicine: a re-emerging therapeutic paradigm.” They all agreed that LSD, psilocybin and MDMA could prove beneficial to some specific patients.
Dr. Johnson continued by stating that
“in the right context, these drugs can help people a lot, especially people who have disorders […]such as end-of-life distress, PTSD, and addiction issues involving tobacco or alcohol.”
The scientists have been carefully monitoring prospective patients, whereas the potential patients have also been analyzed during medication use. Evidently, they required a thorough follow-up.
It seems that while MDMA was tested for PTSD therapy, along with psilocybin for alcohol addiction, the interventions during a short timeframe have shown improvements, benefits.
The study authors claim that the drugs could be more economical in comparison to other costly forms of treatment.
Dr. Johnson reported to the press that the US Food and Drug Administration has previously approved of these early studies, approximately in the 1990s.
Photo Credits wondergressive.com